Clinical Trials Browser

Interventional × Recurrence × tislelizumab × Clear all

Carcinoma, Hepatocellular, Recurrence

NCT03924986 2025-01-31

RATIONALE-309

Phase 3 Completed

263 enrolled 19 charts

Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT03493451 2024-10-26

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Phase 2 Completed

77 enrolled 20 charts

DermatologicLymphoid

Immunoblastic Lymphadenopathy, Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Extranodal NK-T-Cell

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

Phase 1 Completed

75 enrolled 17 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

NCT05277675 2022-03-14

RANT

Phase NA Unknown

160 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT04981665 2022-01-05

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Unknown

50 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT04539444 2021-08-02

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma

Phase 2 Unknown

10 enrolled

Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

Clinical Trials

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

RATIONALE-309

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

RANT

A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma